Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental immune therapy targets deadly childhood brain cancers

NCT ID NCT03334305

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 35 times

Summary

This early-phase study tested whether a custom-made vaccine and special immune cells (T-cells) could be given safely to children with newly diagnosed high-grade gliomas, a very aggressive brain cancer. The treatment used the patient's own tumor to create a vaccine that would train their immune system to attack cancer cells. The study was stopped early, but it aimed to see if this approach could safely boost the body's natural defenses against the tumor.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH GRADE GLIOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Children's National Hospital

    Washington D.C., District of Columbia, 20010, United States

  • Children's of Alabama at UAB

    Birmingham, Alabama, 35233, United States

  • UF Health Shands Children's Hospital

    Gainesville, Florida, 32608, United States

Conditions

Explore the condition pages connected to this study.